Még nem toboroz
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with
Relapsed or Refractory Multiple Myeloma
2025-523815-12-00· 3. fázis· Janssen Cilag International· Forrás
Toboroz
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
NCT07284602· 3. fázis· PureTech· Forrás
Toboroz
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
NCT07194382· 2. fázis· Avalyn Pharma Inc.· Forrás
Toboroz
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT07284758· 2. fázis· C4 Therapeutics, Inc.· Forrás
Toboroz
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
NCT06932562· 3. fázis· European Myeloma Network B.V.· Forrás
Toboroz
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
2024-512503-39-00· 4. fázis· Medizinische Hochschule Hannover· Forrás
Toboroz
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958· 3. fázis· Syndax Pharmaceuticals· Forrás
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903· 3. fázis· Alnylam Pharmaceuticals· Forrás
Toboroz
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
NCT06713837· 3. fázis· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Forrás
Toboroz
“A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive breast cancer patients”
2024-519514-31-00· 2. fázis· Consorzio Oncotech· Forrás
Még nem toboroz
Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission
NCT06618937· 4. fázis· Istituto Giannina Gaslini· Forrás
Toboroz
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574· 3. fázis· Cytokinetics· Forrás
Toboroz
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
2023-509340-10-00· 3. fázis· OSE Immunotherapeutics· Forrás
Fut, nem toboroz
Clinical trial with Mosunetuzumab and Zanubrutinib in patients with relapsed/refractory follicular lymphoma
2023-506049-52-00· 2. fázis· Fondazione Italiana Linfomi Ets· Forrás
Fut, nem toboroz
Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program
NCT06253637· 2. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Fut, nem toboroz
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
NCT02205762· 2/3. fázis· St. Anna Childrens Cancer Research Institute GmbH· Forrás
Toboroz
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS
NCT06189833· 2. fázis· European Myeloma Network B.V.· Forrás
Toboroz
COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease
NCT05873881· 3. fázis· Hamilton Health Sciences Corporation· Forrás
Toboroz
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566· 3. fázis· Ascentage Pharma Group Inc.· Forrás
Toboroz
Phase III trial comparing local radiotherapy alone or with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial.
2022-502775-29-01· 3. fázis· Fondazione Italiana Linfomi Onlus· Forrás
Fut, nem toboroz
Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL
NCT05478512· 2. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Toboroz
Venetoclax in combination with Ibrutinib and Rituximab or conventional
chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients
with Mantle Cell Lymphoma.
2022-501808-96-00· 2. fázis· Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR· Forrás
Toboroz
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
NCT05623319· 2. fázis· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Forrás
Fut, nem toboroz
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
NCT05300282· 1/2. fázis· Fondazione Italiana Linfomi - ETS· Forrás
Toboroz
What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
NCT04436978· 4. fázis· St. Antonius Hospital· Forrás
Toboroz
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· 3. fázis· Anthos Therapeutics, Inc.· Forrás
Toboroz
National Database on Primary Sclerosing Cholangitis (PSC)
NCT05618145· University of Milano Bicocca· Forrás
Contact: Giorgio Bellardini
Fut, nem toboroz
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
NCT05306301· 2. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Fut, nem toboroz
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797· 3. fázis· European Myeloma Network B.V.· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
NCT05249959· 2. fázis· Fondazione Italiana Linfomi - ETS· Forrás
Fut, nem toboroz
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
NCT05058404· 3. fázis· Fondazione Italiana Linfomi - ETS· Forrás
Fut, nem toboroz
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
NCT04722848· 3. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Fut, nem toboroz
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156· 3. fázis· Geron Corporation· Forrás
Toboroz
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
NCT04184505· 3. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Még nem toboroz
A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)
2024-519031-42-00· 3. fázis· Associazione Italiana Per Lo Studio Del Pancreas· Forrás
Toboroz
RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line of therapy in mCRPC patients with adverse prognostic factors (RADAR-1 CRPC)
2024-518623-30-00· 4. fázis· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Forrás
Toboroz
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
NCT04168502· 3. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493· 3. fázis· Epizyme, Inc.· Forrás
Toboroz
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Fut, nem toboroz
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
NCT03610438· 2. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Toboroz
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
NCT04793919· 2. fázis· Associazione Italiana Ematologia Oncologia Pediatrica· Forrás
Fut, nem toboroz
Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with Activated-B-Cell (ABC)-DLBCL at intermediate-high and high risk (IPI ≥2)
NCT03731234· 2. fázis· Fondazione Italiana Linfomi Ets· Forrás
Fut, nem toboroz
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
NCT04096066· 3. fázis· Fondazione EMN Italy Onlus· Forrás
Fut, nem toboroz
MILES5 – A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC
NCT03975114· 2. fázis· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Forrás
Showing 50 of 54.